| Document |
Document Title |
|
WO/2024/094017A1 |
Provided are a GPC3 bispecific antigen binding molecule or an antigen binding fragment thereof, a derivative containing the bispecific antigen binding molecule or the antigen binding fragment thereof, and a pharmaceutical composition. In...
|
|
WO/2024/093042A1 |
Provided are an anti-BSA rabbit monoclonal antibody and use thereof, which belong to the technical field of antibodies. The anti-BSA rabbit monoclonal antibody or an antigen-binding portion thereof specifically binds to BSA. The monoclon...
|
|
WO/2024/093915A1 |
Provided are a protein comprising an amino acid sequence capable of binding to a substrate GPRP peptide fragment, a fibrinogen like protein 1 (FGL1) comprising the amino acid sequence, and a fibrinogen domain (FD) thereof, and an individ...
|
|
WO/2024/098037A1 |
The present disclosure provides chimeric receptor constructs comprising a CD3e extracellular domain and engineered NK and T cells expressing such receptors and methods of making and using same for the treatment of cancer and other diseas...
|
|
WO/2024/094044A1 |
The present disclosure relates to an optimized PAH gene and an expression cassette and use thereof. Specifically, a polynucleotide molecule encoding PAH protein is disclosed. By means of using the polynucleotide molecule, expression cass...
|
|
WO/2024/097603A2 |
Provided herein are methods of producing heterozygous edited animals by injecting zygotes with low amounts of ribonucleoprotein (RNP) complex. The data cited herein show that more heterozygous animals are obtained from zygotes injected w...
|
|
WO/2024/096545A1 |
The present application relates to a microorganism producing purine nucleotides and a method for producing purine nucleotides using same.
|
|
WO/2024/098036A1 |
The subject matter described here relates to anti -PAG antibodies. The subject matter described here also provides a pharmaceutical composition of, or a kit for generating an anti-PAG antibody; a method of making an anti-PAG antibody; a ...
|
|
WO/2024/098042A2 |
Provided herein is a growth selection platform for noncanonical cofactor oxidizing enzymes, the noncanonical cofactor oxidizing enzymes identified thereof, and applications thereof.
|
|
WO/2024/096120A1 |
The present disclosure relates to improving the colonization properties of a bacterial preparation in a host. Specifically, the present disclosure relates to a microorganism wherein at least one gene is modified, said modification improv...
|
|
WO/2024/096038A1 |
The present invention addresses the problem of providing a method for producing active HGF in an industrially advantageous manner, by expressing HGF α chain and HGF β chain in the same host cell. The present disclosure provides a met...
|
|
WO/2024/092713A1 |
Disclosed in the present invention is an MMLV reverse transcriptase mutant. Compared with the amino acid sequence of wild-type MMLV reverse transcriptase, the MMLV reverse transcriptase mutant provided in the present invention has mutati...
|
|
WO/2024/093147A1 |
The present invention relates to an antibody specifically binding to the v5 exon of human CD44 or a fragment thereof. The present invention also relates to a chimeric antigen receptor molecule comprising the antibody or the fragment ther...
|
|
WO/2024/097916A2 |
The present disclosure provides compositions (e.g., pharmaceutical compositions) and methods for treating conditions associated with aberrant expression of KRT17, including psoriasis and certain malignancies. The compositions comprise an...
|
|
WO/2024/098031A1 |
Described herein are methods of modulating ABCB11 gene transcription using antisense oligonucleotides (ASOs) targeting regulatory RNAs, such as promoter-associated RNAs and enhancer RNAs. These methods are useful for increasing the expre...
|
|
WO/2024/095599A1 |
Provided is a method for producing glomus cell-like cells, the method including: (a) a step for inducing differentiation of pluripotent stem cells into autonomic progenitor cells; and (b) a step for culturing the autonomic progenitor cel...
|
|
WO/2024/094002A1 |
The present invention relates to a fructose diphosphate optical probe. Specifically, provided in the present invention is a fructose diphosphate optical probe, which comprises a fructose-1,6-diphosphate sensitive polypeptide and an optic...
|
|
WO/2023/177526A9 |
The disclosure provides nucleic acid molecules (comprising expression cassettes), plasmids, protein molecules, cells (comprising nucleic acid molecules), and recombinant expression systems for producing recombinant cascade reagents for t...
|
|
WO/2024/096506A1 |
The present invention relates to a method for preparing a high-concentration liquid medium having reduced osmotic pressure, and a method for producing a protein of interest by using the medium. When the high-concentration liquid medium i...
|
|
WO/2024/097821A1 |
The present disclosure provides a Nucleotide-Based Enhancement Agent being a compound or a pharmaceutically acceptable salt thereof, comprising from 2 to 30 nucleotides, wherein each nucleotide independently is of Formula (I) or (II): (I...
|
|
WO/2024/093962A1 |
Provided is use of a compact editing tool EbCas12a in gene editing. The EbCas12a has an amino acid sequence set forth in SED ID NO. 1 or 2.
|
|
WO/2024/092769A1 |
Provided is a fusion polypeptide comprising a carrier protein and a polypeptide of interest, wherein the polypeptide of interest is fused to a terminus of the carrier protein or inserted into the carrier protein, and wherein the carrier ...
|
|
WO/2024/092768A1 |
The present invention relates to a thermostable reverse transcriptase and use thereof. The thermostable reverse transcriptase has at least one of mutation positions L333, P65, Q68, P127, P175, E176, G178, G331, T332, F334, and G105, wher...
|
|
WO/2024/094578A1 |
The present invention is directed to seedless fruit producing melon. The present invention also comprises methods for production of said plants and methods for producing seedless melon. Plants and plant parts of the invention comprise at...
|
|
WO/2024/095283A1 |
The present invention discloses a recombinant DNA encoding a protein having an amino acid sequence as set forth in SEQ ID NO: 2, or SEQ ID NO: 4. The present invention further discloses a recombinant vector comprising the recombinant DNA...
|
|
WO/2024/098076A1 |
Aspects of the present disclosure relate generally to methods, compositions, and kits for conjugating cells with magnetic beads. Aspects of the present disclosure also include methods, compositions, and kits for using magnetic bead conju...
|
|
WO/2024/097749A2 |
The present disclosure relates to cultured tissue, methods for production of self-sufficient modified cells for producing cultured tissue. Further, the disclosure provides methods of generating cultured meat products without exogenous ad...
|
|
WO/2024/097307A1 |
The present disclosure features a method of preparing a population of payload-associated cell complexes (PACCs), as well as related methods of use thereof.
|
|
WO/2024/096642A1 |
The present invention relates to a DNA aptamer for the diagnosis of colorectal cancer and, specifically, to a composition and a kit for the diagnosis of colorectal cancer, and a colorectal cancer-specific drug delivery composition, each ...
|
|
WO/2024/093489A1 |
The present invention belongs to the technical field of biomedicine, and provides a control method for continuous evolution of an eukaryotic cell and use thereof. The method comprises the following steps: (1) construction of a stable cel...
|
|
WO/2024/096677A1 |
The present invention relates to a peptide library derived from the vast TIR domains present across various biological species, a construction method therefor, and a novel peptide, screened from this library, which is involved in the TLR...
|
|
WO/2024/098026A2 |
The present disclosure, at least in part, is based on the discovery of novel BCMA antibodies or antigen binding fragments thereof, and genetically modified cells (e.g., iNKT cells, CAR T cells, etc.) expressing chimeric antigen receptors...
|
|
WO/2024/094632A2 |
The invention concerns a genetically engineered bacterium for producing at least one metabolite, peptide or recombinant protein comprising a gene encoding a recombinant protein of interest or at least one gene encoding an enzyme involved...
|
|
WO/2024/092629A1 |
The present invention relates to a CAR-T cell with enhanced efficacy and lifetime, and use of nicotinamide mononucleotide in enhancing the efficacy and lifetime of the CAR-T cell. In addition, the present invention further relates to use...
|
|
WO/2024/097763A1 |
The present application is directed to multiplex intein-based methods and compositions for the generation engineered cells expressing modular polypeptides, for example CARs and CCRs.
|
|
WO/2024/096937A1 |
Affinity reagents are described, including antibodies and aptamers that are cross- reactive with one or more A. ocellatum or P. pillulare antigens. The aptamers and antibodies can detect these antigens in marine organisms or aquaculture ...
|
|
WO/2024/094224A2 |
Provided in the present invention are a PBase protein, a fusion protein, a nucleic acid, a gene integration system, a gene delivery system and the use. The PBase protein retains the abilities of binding to the ITR sequences of a Piggybac...
|
|
WO/2023/278787A9 |
The present disclosure provides methods of treating subjects having decreased bone mineral density or at risk of developing decreased bone mineral density, methods of identifying subjects having an increased risk of developing decreased ...
|
|
WO/2024/094004A1 |
The invention belongs to the technical field of cell immune engineering, and particularly relates to a fully human antigen binding fragment and single chain fragment variable targeting CD123, and a use thereof. The single chain fragment ...
|
|
WO/2024/097941A1 |
A method of treating malignancy in a subject in need thereof is provided. The method includes administering a therapeutically effective amount of a compound that increases the level of one or more of piR_017723, piR_23656, or piR_016745,...
|
|
WO/2024/097644A1 |
Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes (e.g, wherein each complex is of the exemplary formula shown below) comprising a phosphor...
|
|
WO/2024/098054A1 |
Compositions and methods for depleting B cells and/or eliminating neutralizing antibodies, particularly for AA V gene therapy administration, are disclosed. Neutralizing alloantibodies (NAbs) to adeno-associated virus (AAV) occur both na...
|
|
WO/2024/096539A1 |
The present invention relates to a polymer-based nucleic acid molecule (e.g., mRNA) delivery vehicle having an ionization moiety. Specifically, the present invention provides a novel polymer capable of delivering all negatively charged d...
|
|
WO/2024/092350A1 |
Provided herein is a method for preparing the nanoparticle comprising: (i) combining an aqueous phase comprising the nucleic acid with an organic solvent-lipid mixture comprising lipids, wherein the lipids comprise an ionizable lipid and...
|
|
WO/2024/097976A1 |
Compositions and methods of inducing an immune response in a subject having RSV comprising administering a pharmaceutical composition comprising a prophylactic vaccine against RSV infection, wherein the vaccine comprises a live recombina...
|
|
WO/2024/097981A1 |
Disclosed are methods for the diagnosing and staging of cancers including, but not limited to multiple myeloma and treatment regimens incorporating said methods.
|
|
WO/2024/092712A1 |
Disclosed is an MMLV reverse transcriptase mutant. The present invention provides an MMLV reverse transcriptase mutant having mutations at amino acid residue positions 66 and 68 compared with the wild-type MMLV reverse transcriptase amin...
|
|
WO/2024/095130A1 |
Provided herein is an engineered immunoglobulin (Ig) variable domain comprising or capable of comprising at least one non-canonical disulfide bond formed between a first cysteine and a second cysteine, wherein the first and second cystei...
|
|
WO/2024/097448A1 |
Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular, the present technology relates to the use of a recombinant modified vaccinia A...
|
|
WO/2024/092942A1 |
Disclosed are a biomarker for tuberous sclerosis complex-no mutation identified (TSC-NMI) and use thereof. The biomarker is an expression level of an IQGAP2 gene. The IQGAP2 gene can be used as a detection marker of TSC-NMI, and has the ...
|
